Monoclonal Antibody to get Considered as Novel Therapeutic Treatment Regimen for Covid-19 Patients

Release Date: 14-Nov-2020

For the cancer treatment an antibody called as I-006 is getting evaluated at clinical level. It is witnessed that the antibody which is getting evaluated for having anti-cancer activity may have substantial efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and eventually development of an immune response. The antibodies discovered in the patients having asymptomatic Covid-19 also suffering from cancer. The enrolled patients in the clinical trial received CPI-006 in the study. The primary aim of the researchers inclined towards the study was to study and evaluate the efficacy of CPI-006 in the overall enhancement of an anti-tumor immune response.

In the respective clinical trial, 22 patients were enrolled. All the patients that were enrolled in the study had mild-to-moderate COVID-19. For the clinical research, the patients received single dose of 4 different doses of CPI-006. Further evaluation was done to test the treatment safety, symptoms, inflammatory markers and also anti-SARS-CoV-2 antibodies developed in the enrolled patients. All the patients that were enrolled in the study were having comorbidities such as diabetes, hypertension, obesity, pulmonary disorders, and/or cancer. After the introduction of the drug into the patients, the median duration of Covid-19 symptoms was observed to be 8 days. Majority of the patients were discharged from the hospital as sign of improvement was observed.

Antibodies such as IgG and IgM were developed in the patients. Along with antibodies anti-spike protein, peripheral memory B cells and memory effector T cells were also witnessed in the patients. The developed antibodies in the patients were persisted in the patients for minimum 84 days. In all the enrolled patients no adverse signs were observed. Therefore, it was concluded that the antibody can be novel therapy against Covod-19 which has infected more than million patients across the globe.